Adjuvant and Neoadjuvant Therapies for Early Stage Breast Cancer, Including SABCS Updates

Results from clinical trials show that surgery followed by adjuvant systemic therapy may not be the optimal strategy to maximize a patient's chance of survival from triple-negative or HER2-positive breast cancers. Administering neoadjuvant therapy before surgery provides an opportunity to directly observe the efficacy of a particular systemic therapy regimen. Clinicians are challenged to stay up-to-date on new approaches and options for neoadjuvant /adjuvant systemic therapy so they can provide appropriate care using a shared decision making process with the patient, taking into account patient and disease characteristics including risk of recurrence, and weighing the potential benefits and risks of each option. In addition, it is important for clinicians to be aware of new supportive care interventions available to improve the quality of life of patients.

Target Audience

This educational program is designed to meet the educational needs of physicians, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with breast cancer.

Learning Objectives

Following this program, participants should be able to:

  • Compare and contrast data on the clinical safety and efficacy of neoadjuvant regimens in early stage breast cancer.
  • Recognize key patient and clinical factors that influence selection of systemic adjuvant therapy.
  • Discuss clinical data of new and emerging supportive care interventions to improve quality of life of patients undergoing neoadjuvant/adjuvant chemotherapy.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • AstraZeneca
  • Celgene Corporation
  • Daiichi Sankyo, Inc.
  • Genentech
  • Genomic Health, Inc.
  • Novartis
  • Pfizer Inc.

This program is supported by an independent educational grant from Merck & Co., Inc.

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 0.93 ANCC contact hours
  • 1.00 Participation
Course opens: 
03/15/2020
Course expires: 
03/15/2021
Cost:
$0.00

Jame Abraham, MD
Case Comprehensive Medical Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute

Ami N. Shah, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Definitions 

NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. 

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

The faculty listed below discloses no relevant financial relationships:

Jame Abraham, MD

The faculty listed below discloses the following relevant financial relationships:

Ami N. Shah, MD
AbbVie, Inc.: Advisory Board Member

NCCN Staff Disclosures

The NCCN Activity Planning staff listed below discloses no relevant financial relationships:

Melissa Esplen; Mark A. Geisler; Kristina A. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Kathy Ann Smith, CHCP; Sarah Weinstein

The NCCN Clinical staff listed below discloses no relevant financial relationships:

Jennifer Burns; Susan D. Darlow, PhD; Mary A. Dwyer, MS; Rashmi Kumar, PhD

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 0.93 contact hours.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hours (0.1 CEUs) of continuing education credit. UAN: JA4008196-0000-20-027-H01-P

Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 3/15/2021. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 0.93 ANCC contact hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need: